A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Latest Information Update: 24 Apr 2023
At a glance
- Drugs Erlotinib (Primary) ; Rilotumumab (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung-MAP Sub-Study
- 17 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 14 Dec 2017 Planned End Date changed from 1 May 2022 to 1 Apr 2022.
- 18 Oct 2017 Results of Lung-Map substudies (S1400A, B, C, D and E) presented at the 18th World Conference on Lung Cancer